MacroGenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 02, 2021 at 04:01 pm EDT
Share
MacroGenics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 15.66 million compared to USD 18.25 million a year ago. Net loss was USD 52.89 million compared to USD 36.04 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 0.66 a year ago. Diluted loss per share from continuing operations was USD 0.86 compared to USD 0.66 a year ago.
For the nine months, revenue was USD 63.3 million compared to USD 52.19 million a year ago. Net loss was USD 144.09 million compared to USD 127.65 million a year ago. Basic loss per share from continuing operations was USD 2.42 compared to USD 2.49 a year ago. Diluted loss per share from continuing operations was USD 2.42 compared to USD 2.49 a year ago.
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
MACROGENICS, INC. 
